What is NBO Pharma Inc?
Incorporated in 2021, NBO Pharma Inc is a clinical-stage pharmaceutical enterprise dedicated to the development of novel treatments for Idiopathic Intracranial Hypertension (IIH). Currently, there are no FDA-approved pharmacological interventions for this debilitating condition, positioning NBO Pharma as a first-mover in the space. The company utilizes a strategic re-purposing model, leveraging octreotide acetate—a well-characterized orphan drug—and optimizing it through a proprietary intranasal formulation. By focusing on nasal bioavailability, the firm aims to improve patient outcomes and streamline the regulatory pathway for its lead candidate, which is currently advancing through critical clinical trials.
How much funding has NBO Pharma Inc raised?
NBO Pharma Inc has raised a total of $7.6M across 1 funding round:
Private Equity
$7.6M
Private Equity (2026): $7.6M, investors not publicly disclosed
Key Investors in NBO Pharma Inc
Undisclosed Investor
An institutional capital provider specializing in late-stage biotech and pharmaceutical growth equity.
Undisclosed Investor
A strategic investment firm focused on high-impact medical innovations and orphan drug development.
Undisclosed Investor
A specialized life sciences investor providing capital to companies addressing critical gaps in neurological therapeutics.
What's next for NBO Pharma Inc?
With the recent capital injection, NBO Pharma Inc is well-positioned to accelerate its clinical development pipeline and scale its operational infrastructure. The strategic focus will likely shift toward completing ongoing trials and preparing for potential regulatory submissions. As the company navigates the complexities of orphan drug development, the current financing provides the necessary runway to conduct rigorous efficacy studies and establish manufacturing partnerships. Investors are closely monitoring the firm's progress, as successful clinical validation could establish a new standard of care for IIH patients globally, potentially unlocking significant market value in the rare disease pharmaceutical sector.
See full NBO Pharma Inc company page
